ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
|
||
(Address of principal executive offices) |
(Zip Code) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
☒ | Smaller reporting company | |||||
Emerging growth company |
• | pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of assets; |
• | provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and |
• | provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements. |
Exhibit Number |
Description | |
3.1 |
||
3.2 |
||
4.1 |
||
4.2 |
||
10.1# |
||
10.2# |
||
10.3# |
||
10.4# |
||
10.5# |
||
10.6# |
||
10.7 |
||
10.8† |
||
10.9† |
10.10 |
||
10.11 |
||
10.12# |
||
10.13# |
||
10.14† |
||
10.15# |
||
10.16# |
||
10.17# |
||
10.18# |
||
10.19# |
||
10.20# |
||
10.21† |
||
10.22† |
||
10.23† |
10.24+ |
||
10.25+ |
||
21.1 |
||
23.1 |
||
31.1* |
||
31.2* |
||
32.1* |
||
32.2* |
||
101.INS |
Inline XBRL Instance Document | |
101.SCH |
Inline XBRL Taxonomy Extension Schema Document | |
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document | |
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase Document | |
101.LAB |
Inline XBRL Taxonomy Extension Label Linkbase Document | |
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document | |
104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* |
Filed herewith. |
# |
Indicates a management contract or any compensatory plan, contract or arrangement. |
† |
Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and Exchange Commission. |
+ |
Schedules to the Sublease and Lease have been omitted pursuant to Item 601(b)(2) of Regulation S-K because they contain information that is both (i) not material and (ii) of the type that the registrant treats as private and confidential. The registrant will furnish copies of any such schedules to the U.S. Securities and Exchange Commission upon request. |
ALLOVIR, INC. | ||||||
Date: March 30, 2022 |
By: |
/s/ Diana Brainard | ||||
Diana Brainard | ||||||
Chief Executive Officer and Director (Principal Executive Officer) |
Signature |
Title |
Date | ||
/s/ Diana Brainard, MD |
Chief Executive Officer and Director (Principal Executive Officer) |
March 30, 2022 | ||
Diana Brainard |
||||
/s/ Vikas Sinha |
President, Chief Financial Officer and Director (Principal Financial Officer and Principal Accounting Officer) |
March 30, 2022 | ||
Vikas Sinha |
||||
* |
Executive Director |
March 30, 2022 | ||
David Hallal |
||||
* |
Director |
March 30, 2022 | ||
Jeffrey Bornstein |
||||
* |
Director |
March 30, 2022 | ||
Malcolm Brenner, MD, PhD |
||||
* |
Director |
March 30, 2022 | ||
Ansbert Gadicke, MD |
||||
* |
Director |
March 30, 2022 | ||
Morana Jovan-Embiricos, PhD |
||||
* |
Director |
March 30, 2022 | ||
Juan F. Vera, MD |
||||
* |
Director |
March 30, 2022 | ||
John Wilson |
By: |
/s/ Diana Brainard, MD | |
Diana Brainard Attorney-in-Fact * Pursuant to Power of Attorney |